Abstract:Background CDK4/6 inhibitors combined with endocrine therapy has become the preferred treatment approach for patients with estrogen receptor-positive metastatic breast cancer. However, the predictive biomarkers and mechanisms of innate resistance to CDK4/6 inhibitors remain largely unknown. We sought to elucidate the molecular hallmarks and therapeutically actionable features of patients with resistance to CDK4/6 inhibitors. Methods A total of 36 patients received palbociclib and endocrine therapy were included in this study as the discovery cohort. Next-generation sequencing of circulating tumour DNA in these patients was performed to evaluate somatic alterations associated with innate resistance to palbociclib. Then the candidate biomarker was validated in another independent cohort of 104 patients and publicly available datasets. The resistance was verified in parental MCF-7 and T47D cells, as well as their derivatives with small interfering RNA transfection and lentivirus infection. The relevant mechanism was examined by RNA sequencing, chromatin immunoprecipitation and luciferase assay. Patient-derived organoid and patient-derived xenografts studies were utilized to evaluated the antitumor activity of rational combinations. Results In the discovery cohort, S6K1 amplification (3/35, 9%) was identified as an important reason for innate resistance to CDK4/6 inhibitors. In the independent cohort, S6K1 was overexpressed in 15/104 (14%) patients. In those who had received palbociclib treatment, patients with high-expressed S6K1 had significantly worse progression free survival than those with low S6K1 expression (hazard ratio = 3.0, P = 0.0072). Meta-analysis of public data revealed that patients with S6K1 amplification accounted for 12% of breast cancers. Breast cancer patients with high S6K1 expression had significantly worse relapse-free survival (hazard ratio = 1.31, P < 0.0001). In breast cancer cells, S6K1 overexpression, caused by gene amplification, was sufficient to promote resistance to palbociclib. Mechanistically, S6K1 overexpression increased the expression levels of G1/S transition-related proteins and the phosphorylation of Rb, mainly through the activation of c-Myc pathway. Notably, this resistance could be abrogated by the addition of mTOR inhibitor, which blocked the upstream of S6K1, in vitro and in vivo. Conclusions S6K1 amplification is an important mechanism of innate resistance to palbociclib in breast cancers. Breast cancers with S6K1 amplification could be considered for combinations of CDK4/6 and S6K1 antagonists.

<i>P16</i>methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib

P16 Methylation Increases the Sensitivity of Cancer Cells to the CDK4/6 Inhibitor Palbociclib.

The effects of p16 gene methylation on the risk of non-small cell lung cancer

P16 Methylation Leads to Paclitaxel Resistance of Advanced Non-Small Cell Lung Cancer

P16-specific DNA Methylation by Engineered Zinc Finger Methyltransferase Inactivates Gene Transcription and Promotes Cancer Metastasis

CDK4/6 Inhibition Stabilizes Disease in Patients with P16-Null Non-Small Cell Lung Cancer and is Synergistic with Mtor Inhibition.

A Novel Method of Microarray Quantitave Analysis of P16 CPG Island Methylation in Leukemia Cells from Patients with Hematological Malignancies.

The CDK4/6 Inhibitor Palbociclib Induces Cell Senescence of High-grade Serous Ovarian Cancer Through Acetylation of p53

P16 Promotes the Growth and Mobility Potential of Breast Cancer Both in Vitro and in Vivo: the Key Role of the Activation of IL-6/JAK2/STAT3 Signaling

Driving effect of P16 methylation on telomerase reverse transcriptase-mediated immortalization and transformation of normal human fibroblasts

Methylation of CpG Islands of P16 Associated with Progression of Primary Gastric Carcinomas

S6K1 Amplification Confers Innate Resistance to CDK4/6 Inhibitors Through Activating C-Myc Pathway in Patients with Estrogen Receptor-Positive Breast Cancer

Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2‐Hippo signaling pathway

Hydroxymethylated-P16 Allele Is Transcription-Inactive

Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells

Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer

DNA Hydroxymethylation Increases the Susceptibility of Reactivation of Methylated P16 Alleles in Cancer Cells

BSTM-01. POTENT ANTI-TUMOR EFFICACY OF PALBOCICLIB IN TREATMENT-NAÏVE H3.3K27M-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA

B-cell Specific Moloney Leukemia Virus Insertion Site 1 Promotes Proliferation of Pancreatic Cancer Cells PANC-1 Via Inhibiting the Expression of P16 Gene

Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma